WEDNESDAY, April 24, 2024 -- For patients with atopic dermatitis (AD), dupilumab is safe and has sustained effectiveness across various patient-reported outcome measures, according to a study published online April 21 in the Journal of the American Academy of Dermatology.

Junfen Zhang, M.D., from University Medical Center Groningen in the Netherlands, and colleagues examined patient-reported outcome measures and the safety of dupilumab in patients with moderate-to-severe AD for up to five years. Data were included for 1,223 patients: 1,108 adults and 115 pediatric patients.

The researchers found that after one year of treatment or longer, the mean Patient-Oriented Eczema Measure, Dermatology Life Quality Index, and Numeric rating scale-pruritis varied from 7.8 to 8.7, 3.5 to 4.2, and 2.9 to 3.1, respectively, in adults and from 8.9 to 10.9, 4.4 to 6.4, and 3.0 to 3.7, respectively, in pediatric patients. In adults, overall work impairment decreased from 40.1 percent to a range of 13.3 to 16.3 percent at follow-up. Less favorable treatment response was generally seen for class I obesity and itch-dominant patients. Overall, 66.8 percent of patients reported one or more adverse event, with the most common being conjunctivitis (33.7 percent).

"In addition to a favorable safety profile, dupilumab has shown rapid and sustained effectiveness in improving various aspects of patient-reported outcomes in both adult and pediatric populations in a long follow-up duration," the authors write. "This highlights the treatment benefits of dupilumab from patients' perspectives."

Several authors disclosed ties to pharmaceutical companies, including Sanofi and Regeneron, which manufacture dupilumab.